Oral Paclitaxel Trial In Recurrent and Metastatic Breast Cancer As 1st Line Therapy
Status:
Recruiting
Trial end date:
2022-03-31
Target enrollment:
Participant gender:
Summary
To compare and evaluate the efficacy and safety of Liporaxel® solution (oral paclitaxel) and
Taxol® (IV paclitaxel) on recurrent or metastatic breast cancer.